Details for New Drug Application (NDA): 020131
✉ Email this page to a colleague
The generic ingredient in PROHANCE is gadoteridol. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the gadoteridol profile page.
Summary for 020131
| Tradename: | PROHANCE |
| Applicant: | Bracco |
| Ingredient: | gadoteridol |
| Patents: | 0 |
Pharmacology for NDA: 020131
| Mechanism of Action | Magnetic Resonance Contrast Activity |
Suppliers and Packaging for NDA: 020131
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131 | NDA | BRACCO DIAGNOSTICS INC | 0270-1111 | 0270-1111-01 | 5 VIAL, SINGLE-DOSE in 1 BOX (0270-1111-01) / 10 mL in 1 VIAL, SINGLE-DOSE |
| PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131 | NDA | BRACCO DIAGNOSTICS INC | 0270-1111 | 0270-1111-02 | 5 VIAL, SINGLE-DOSE in 1 BOX (0270-1111-02) / 15 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 279.3MG/ML | ||||
| Approval Date: | Nov 16, 1992 | TE: | AP | RLD: | Yes | ||||
Expired US Patents for NDA 020131
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Start Trial | ⤷ Start Trial |
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Start Trial | ⤷ Start Trial |
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Start Trial | ⤷ Start Trial |
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
